Claims Scope:

Patent issued July 17, 2018. 

≥80% Sequence Identity – Methods only 

Methods of treating cancer using a composition of lentiviral particle encoding an shRNA or a miRNA capable of inhibiting production of an enzyme of the mevalonate pathway, with shRNA having at least 80% percent identity to SEQ 1-4, or, microRNA having at least 80% identity to SEQ 5-10.